Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Biocodex
(https://biocodex.com) 📸 Data Snapshot: May 29, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Biocodex providing healthcare solutions worldwide. – Biocodex.com (https://biocodex.com)
Title
Biocodex providing healthcare solutions worldwide. – Biocodex.com
Meta
Welcome to Biocodex corporate website! Please visit our pages to learn about our history, our expertise and our international expansion.
H1 Biocodex providing healthcare solutions worldwide.
H2 Empowering everyone to live fully
H2 Discover Biocodex’s new Corporate Press Kit
H2 THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases
H2 Biocodex commits to reducing its carbon footprint by 30% by 2032 and earns the “Engagé RSE” label
H2 What's new at Biocodex
H2 Biocodex Corporate Press Kit
H2 Biocodex Announces Strategic Licensing Agreement with THX Pharma
H2 Step inside Beauvais: our new corporate film
H2 Our focus
H2 Microbiota care
H2 Women’s health
H2 Orphan diseases
H2 Our heritage
NAV_HEADER_HEADING_REPEATED_FOOTER Biocodex providing healthcare solutions worldwide. – Biocodex.com (https://biocodex.com/en/)
Title
Biocodex providing healthcare solutions worldwide. – Biocodex.com
Meta
Welcome to Biocodex corporate website! Please visit our pages to learn about our history, our expertise and our international expansion.
H1 Biocodex providing healthcare solutions worldwide.
H2 Empowering everyone to live fully
H2 Discover Biocodex’s new Corporate Press Kit
H2 THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases
H2 Biocodex commits to reducing its carbon footprint by 30% by 2032 and earns the “Engagé RSE” label
H2 What's new at Biocodex
H2 Biocodex Corporate Press Kit
H2 Biocodex Announces Strategic Licensing Agreement with THX Pharma
H2 Step inside Beauvais: our new corporate film
H2 Our focus
H2 Microbiota care
H2 Women’s health
H2 Orphan diseases
H2 Our heritage
HEADER_HEADING_REPEATED_BODY THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases – Biocodex.com (https://biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/)
Title
THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases – Biocodex.com
Meta
Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada.
H1 THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases
NAV_HEADER_HEADING_REPEATED_BODY Microbiota care – Biocodex.com (https://biocodex.com/en/our-focus/biocodex-microbiota-care/)
Title
Microbiota care – Biocodex.com
Meta
Biocodex Microbiota Mission is rooted in Biocodex heritage as a pioneer in gut microbiota and we belive it is important for human health.
H1 Microbiota care
H2 Microbiota care
H2 Biocodex’s solutions for microbiota care
H2 The Biocodex Microbiota Institute
H2 The Biocodex Microbiota Foundation
H2 Want to know more?
H3 Our focus on microbiota care is threefold:
H3 1Solutions
H3 2Research
H3 3Education
H3 Our heritage
H3 Orphan diseases
H3 Women’s health
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://biocodex.com) Biocodex providing healthcare solutions worldwide. – Biocodex.com
Biocodex at a glance Biocodex at a glance In the spotlight [H1] Biocodex providing healthcare solutions worldwide. [H2] What's new at Biocodex [IMG: Biocodex identity] Our new Corporate Press Kit offers a comprehensive look at Biocodex — our mission, our expertise and the vision that drives us forward. From pioneering microbiota research to advancing women’s health and rare disease solutions, it highlights how Biocodex continues to transform science into meaningful health solutions for patients around the world. More than a company presentation, it reflects our commitment to innovation, responsibility and long-term impact in global healthcare.Discover the story, values and ambition that shape Biocodex today. Download the Press Kit Biocodex has signed a strategic licensing agreement with THX Pharma covering two drug candidates targeting three rare diseases (Batten, Gaucher, and Niemann-Pick type C), reinforcing its commitment to addressing high unmet medical needs. Read the full Press Release Step inside our Beauvais industrial site, where expertise, quality, and team commitment come together every day. This new corporate film highlights our Made in France pharmaceutical excellence, supporting patients in over 100 countries through high standards and trusted know-how. Watch the film [H2] Our focus [IMG: A family of four with a mother, a father, a younger daughter and an oldest brother standing and playing with each other in their living room by their sofa.] [H2] Microbiota care At Biocodex, we believe that understanding – and acting on – microbiota is important to the future of human health. Rooted in our heritage as pioneer in gut microbiota, we aim to become the global #1 in microbiota care. [IMG: group of four young women looking and talking to each other outside.] [H2] Women’s health As a pioneer in feminine hygiene products and a market leader in France and Belgium, we aim to continue supporting women throughout the world daily and at every stage of their lives. We innovate constantly to bring effective solutions for women's health, comfort and well-being. Our commitment to women includes effective quality products, expert advice and a responsible attitude to the environment and society at large. [IMG: Father carries his baby boy on the shoulder while they walk through the field in the nature] [H2] Orphan diseases Biocodex develops and markets drugs for patients with severe orphan diseases. In the early 1990’s, we developed an anti-epileptic drug indicated for a newly discovered rare and severe epileptic disorder. Since then, we have been committed to raising awareness of rare epilepsies alongside healthcare professionals, patients and caregivers. [IMG: Nicolas COUDURIER] Growing while remaining agile by capitalizing on our values.Nicolas COUDURIER Chief Executive Officer at BIOCODEX~1 900employees worldwide€ 677MIn 202517subsidiaries+100Distribution partners Our development Biocodex is a family-owned company founded 70 years ago to market the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Biocodex has since expanded its expertise in gut microbiota, evolving from French pioneer to an international player in the microbiota realm. Our heritage
3238 chars
SUB-PAGE (https://biocodex.com/en/) Biocodex providing healthcare solutions worldwide. – Biocodex.com
Biocodex at a glance Biocodex at a glance In the spotlight [H1] Biocodex providing healthcare solutions worldwide. [H2] What's new at Biocodex [IMG: Biocodex identity] Our new Corporate Press Kit offers a comprehensive look at Biocodex — our mission, our expertise and the vision that drives us forward. From pioneering microbiota research to advancing women’s health and rare disease solutions, it highlights how Biocodex continues to transform science into meaningful health solutions for patients around the world. More than a company presentation, it reflects our commitment to innovation, responsibility and long-term impact in global healthcare.Discover the story, values and ambition that shape Biocodex today. Download the Press Kit Biocodex has signed a strategic licensing agreement with THX Pharma covering two drug candidates targeting three rare diseases (Batten, Gaucher, and Niemann-Pick type C), reinforcing its commitment to addressing high unmet medical needs. Read the full Press Release Step inside our Beauvais industrial site, where expertise, quality, and team commitment come together every day. This new corporate film highlights our Made in France pharmaceutical excellence, supporting patients in over 100 countries through high standards and trusted know-how. Watch the film [H2] Our focus [IMG: A family of four with a mother, a father, a younger daughter and an oldest brother standing and playing with each other in their living room by their sofa.] [H2] Microbiota care At Biocodex, we believe that understanding – and acting on – microbiota is important to the future of human health. Rooted in our heritage as pioneer in gut microbiota, we aim to become the global #1 in microbiota care. [IMG: group of four young women looking and talking to each other outside.] [H2] Women’s health As a pioneer in feminine hygiene products and a market leader in France and Belgium, we aim to continue supporting women throughout the world daily and at every stage of their lives. We innovate constantly to bring effective solutions for women's health, comfort and well-being. Our commitment to women includes effective quality products, expert advice and a responsible attitude to the environment and society at large. [IMG: Father carries his baby boy on the shoulder while they walk through the field in the nature] [H2] Orphan diseases Biocodex develops and markets drugs for patients with severe orphan diseases. In the early 1990’s, we developed an anti-epileptic drug indicated for a newly discovered rare and severe epileptic disorder. Since then, we have been committed to raising awareness of rare epilepsies alongside healthcare professionals, patients and caregivers. [IMG: Nicolas COUDURIER] Growing while remaining agile by capitalizing on our values.Nicolas COUDURIER Chief Executive Officer at BIOCODEX~1 900employees worldwide€ 677MIn 202517subsidiaries+100Distribution partners Our development Biocodex is a family-owned company founded 70 years ago to market the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Biocodex has since expanded its expertise in gut microbiota, evolving from French pioneer to an international player in the microbiota realm. Our heritage
3238 chars
SUB-PAGE (https://biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/) THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases – Biocodex.com
11 February 2026 Press release Read the press release here FRRead the press release here ENBiocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada. The total deal value is up to €173 million, including a €12 million upfront payment, up to €161 million in development and commercialization milestone payments, and tiered double-digit royalties on net sales.THX Pharma (Theranexus), a biopharmaceutical company specializing in the treatment of rare neurological diseases, and Biocodex, an independent international pharmaceutical group, announce the execution of a strategic licensing agreement to advance the development of two drug candidates in three rare diseases with high unmet medical needs: Batten disease with Batten-1, and Gaucher disease and Niemann-Pick disease type C with TX01.These genetically inherited diseases, often affecting pediatric populations, cause severe and progressive visceral, hematological, or neurological impairments, with a major impact on patients’ quality of life and life expectancy. For some of these conditions, there are either no or only very limited therapeutic options, making each development program a considerable scientific, medical, and human progress.In this context, Biocodex will hold two licenses:an exclusive global license for the development and commercialization of Batten-1, a drug candidate developed by THX Pharma for the treatment of juvenile Batten disease (CLN3),a regional exclusive license covering the United States and Canada for the development and commercialization of TX01, a new formulation of an already approved compound for the treatment of Gaucher disease and Niemann-Pick disease type C.Under the terms of the agreement, THX Pharma will receive total payments of up to €173 million, including €12 million upfront payment and up to €161 million in development and sales milestone payments, as well as tiered double-digit royalties on net sales. As part of the collaboration, THX Pharma will lead the clinical development of the programs, with financial and scientific support from Biocodex. The latter will be responsible for compassionate use programs, market access, and commercialization activities in the territories covered by each license.This agreement is aligned with Biocodex’s longstanding commitment to rare neurological diseases. It builds on the expertise developed over more than thirty years, through an approach that combines scientific rigor, long-term clinical development, and a strong focus on the life journey of patients and their families, beyond the treatment alone.The shared ambition of Biocodex and THX Pharma is to advance therapeutic solutions where unmet needs remain significant, drawing on science, partnership, and ongoing dialogue with all stakeholders, including healthcare professionals and patient advocacy groups.« This strategic agreement with Biocodex represents a major step forward and a significant value-creation milestone for THX Pharma. It validates the scientific and strategic value of our assets by partnering with a leading French pharmaceutical company with strong clinical development capabilities, recognized industrial and regulatory expertise, and a solid international commercial presence in the field of rare neurological diseases. Moreover, this alliance with Biocodex enables the launch of a more ambitious project, both in Europe and in the United States, thereby maximizing our chances of success for the benefit of patients. Together, we will bring forward innovative therapeutic solutions in three rare diseases affecting thousands of people worldwide: Batten disease, Niemann-Pick disease type C, and Gaucher disease. » Mathieu Charvériat, President and Chief Executive Officer of THX Pharma, stated« By partnering with THX Pharma, Biocodex is fully aligned with its innovation strategy dedicated to rare diseases with high unmet medical needs. Building on the experience gained with Diacomit® in Dravet syndrome, we were convinced by THX Pharma’s scientific expertise and the strong alignment with our values of innovation in the service of health. We are also pleased to continue this commitment alongside dedicated research organizations, such as Beyond Batten Disease Foundation, in the interest of patients and their families. » Nicolas Coudurier, Chief Executive Officer of BiocodexAbout Batten-1Batten-1 is currently preparing for a Phase 3 clinical trial, with initiation planned for 2026. Juvenile Batten disease (CLN3) is an ultra-rare pediatric neurodegenerative disorder leading to progressive loss of vision, cognitive and motor functions, and ultimately death in early adulthood. No treatment has been approved to date. Batten-1 aims to become the first available therapy for this condition. This license reflects a long-term ambition, with an international launch targeted around 2030. As part of the collaboration, THX Pharma will lead the Phase 3 study of Batten-1, with scientific and financial support from Biocodex. Biocodex will be responsible for obtaining marketing authorizations, market access activities, and commercialization in the territories covered by the licenses.About TX01TX01 is based on an adapted oral formulation of an already approved active ingredient. It is intended for the treatment of two rare lysosomal diseases:Niemann-Pick disease type C, a severe neurodegenerative disorder causing progressive decline in motor and cognitive functions, with reduced life expectancy,Gaucher disease type 1, a rare metabolic disorder characterized by lipid accumulation in certain organs, potentially leading to hematological, skeletal, and visceral complications.This approach aims to improve treatment administration and better address the specific needs of these patients..
5825 chars
SUB-PAGE · THIN (https://biocodex.com/en/our-focus/biocodex-microbiota-care/) Microbiota care – Biocodex.com
0 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
18Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 7 | 0 |
| /en/ | 7 | 0 |
| /en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/ | 2 | 0 |
| /en/our-focus/biocodex-microbiota-care/ | 2 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.biocodex.com/en/",
"url": "https://www.biocodex.com/en/",
"name": "Biocodex providing healthcare solutions worldwide. - Biocodex.com",
"isPartOf": {
"@id": "https://www.biocodex.com/en/#website"
},
"about": {
"@id": "https://www.biocodex.com/en/#organization"
},
"datePublished": "2021-03-10T10:47:28+00:00",
"dateModified": "2021-12-27T14:31:28+00:00",
"description": "Welcome to Biocodex corporate website! Please visit our pages to learn about our history, our expertise and our international expansion.",
"breadcrumb": {
"@id": "https://www.biocodex.com/en/#breadcrumb"
},
"inLanguage": "en-GB",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.biocodex.com/en/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://www.biocodex.com/en/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Biocodex"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.biocodex.com/en/#website",
"url": "https://www.biocodex.com/en/",
"name": "Biocodex.com",
"description": "Un site utilisant WordPress",
"publisher": {
"@id": "https://www.biocodex.com/en/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.biocodex.com/en/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-GB"
},
{
"@type": "Organization",
"@id": "https://www.biocodex.com/en/#organization",
"name": "Biocodex",
"url": "https://www.biocodex.com/en/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-GB",
"@id": "https://www.biocodex.com/en/#/schema/logo/image/",
"url": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"contentUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"width": 840,
"height": 168,
"caption": "Biocodex"
},
"image": {
"@id": "https://www.biocodex.com/en/#/schema/logo/image/"
},
"sameAs": [
"https://x.com/microbiota_inst",
"https://www.linkedin.com/company/biocodex/"
]
}
]
}
/en/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.biocodex.com/en/",
"url": "https://www.biocodex.com/en/",
"name": "Biocodex providing healthcare solutions worldwide. - Biocodex.com",
"isPartOf": {
"@id": "https://www.biocodex.com/en/#website"
},
"about": {
"@id": "https://www.biocodex.com/en/#organization"
},
"datePublished": "2021-03-10T10:47:28+00:00",
"dateModified": "2021-12-27T14:31:28+00:00",
"description": "Welcome to Biocodex corporate website! Please visit our pages to learn about our history, our expertise and our international expansion.",
"breadcrumb": {
"@id": "https://www.biocodex.com/en/#breadcrumb"
},
"inLanguage": "en-GB",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.biocodex.com/en/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://www.biocodex.com/en/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Biocodex"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.biocodex.com/en/#website",
"url": "https://www.biocodex.com/en/",
"name": "Biocodex.com",
"description": "Un site utilisant WordPress",
"publisher": {
"@id": "https://www.biocodex.com/en/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.biocodex.com/en/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-GB"
},
{
"@type": "Organization",
"@id": "https://www.biocodex.com/en/#organization",
"name": "Biocodex",
"url": "https://www.biocodex.com/en/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-GB",
"@id": "https://www.biocodex.com/en/#/schema/logo/image/",
"url": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"contentUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"width": 840,
"height": 168,
"caption": "Biocodex"
},
"image": {
"@id": "https://www.biocodex.com/en/#/schema/logo/image/"
},
"sameAs": [
"https://x.com/microbiota_inst",
"https://www.linkedin.com/company/biocodex/"
]
}
]
}
/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/",
"url": "https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/",
"name": "THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases - Biocodex.com",
"isPartOf": {
"@id": "https://www.biocodex.com/en/#website"
},
"primaryImageOfPage": {
"@id": "https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/#primaryimage"
},
"image": {
"@id": "https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/#primaryimage"
},
"thumbnailUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Background-press@2x-1-scaled.jpg",
"datePublished": "2026-02-11T09:21:09+00:00",
"dateModified": "2026-02-11T09:21:12+00:00",
"description": "Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada.",
"breadcrumb": {
"@id": "https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/#breadcrumb"
},
"inLanguage": "en-GB",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-GB",
"@id": "https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/#primaryimage",
"url": "https://www.biocodex.com/wp-content/uploads/2021/04/Background-press@2x-1-scaled.jpg",
"contentUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Background-press@2x-1-scaled.jpg",
"width": 2560,
"height": 889
},
{
"@type": "BreadcrumbList",
"@id": "https://www.biocodex.com/en/thx-pharma-and-biocodex-announce-a-strategic-licensing-agreement-covering-three-rare-diseases/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Biocodex",
"item": "https://www.biocodex.com/en/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Press",
"item": "https://www.biocodex.com/en/press/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Biocodex strengthens its commitment to workplace Well-Being and Inclusion"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.biocodex.com/en/#website",
"url": "https://www.biocodex.com/en/",
"name": "Biocodex.com",
"description": "Un site utilisant WordPress",
"publisher": {
"@id": "https://www.biocodex.com/en/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.biocodex.com/en/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-GB"
},
{
"@type": "Organization",
"@id": "https://www.biocodex.com/en/#organization",
"name": "Biocodex",
"url": "https://www.biocodex.com/en/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-GB",
"@id": "https://www.biocodex.com/en/#/schema/logo/image/",
"url": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"contentUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"width": 840,
"height": 168,
"caption": "Biocodex"
},
"image": {
"@id": "https://www.biocodex.com/en/#/schema/logo/image/"
},
"sameAs": [
"https://x.com/microbiota_inst",
"https://www.linkedin.com/company/biocodex/"
]
}
]
}
/en/our-focus/biocodex-microbiota-care/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/",
"url": "https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/",
"name": "Microbiota care - Biocodex.com",
"isPartOf": {
"@id": "https://www.biocodex.com/en/#website"
},
"primaryImageOfPage": {
"@id": "https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/#primaryimage"
},
"image": {
"@id": "https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/#primaryimage"
},
"thumbnailUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Background-microbiota-mission@2x-scaled.jpg",
"datePublished": "2021-03-22T15:43:56+00:00",
"dateModified": "2024-02-14T13:25:26+00:00",
"description": "Biocodex Microbiota Mission is rooted in Biocodex heritage as a pioneer in gut microbiota and we belive it is important for human health.",
"breadcrumb": {
"@id": "https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/#breadcrumb"
},
"inLanguage": "en-GB",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/"
]
}
]
},
{
"@type": "ImageObject",
"inLanguage": "en-GB",
"@id": "https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/#primaryimage",
"url": "https://www.biocodex.com/wp-content/uploads/2021/04/Background-microbiota-mission@2x-scaled.jpg",
"contentUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Background-microbiota-mission@2x-scaled.jpg",
"width": 2560,
"height": 889,
"caption": "A family of four with a mother, a father, a younger daughter and an oldest brother standing and playing with each other in their living room by their sofa."
},
{
"@type": "BreadcrumbList",
"@id": "https://www.biocodex.com/en/our-focus/biocodex-microbiota-care/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Biocodex",
"item": "https://www.biocodex.com/en/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Our focus",
"item": "https://www.biocodex.com/en/our-focus/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Microbiota care"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.biocodex.com/en/#website",
"url": "https://www.biocodex.com/en/",
"name": "Biocodex.com",
"description": "Un site utilisant WordPress",
"publisher": {
"@id": "https://www.biocodex.com/en/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.biocodex.com/en/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-GB"
},
{
"@type": "Organization",
"@id": "https://www.biocodex.com/en/#organization",
"name": "Biocodex",
"url": "https://www.biocodex.com/en/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-GB",
"@id": "https://www.biocodex.com/en/#/schema/logo/image/",
"url": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"contentUrl": "https://www.biocodex.com/wp-content/uploads/2021/04/Biocodex_corporate-C@2x.svg",
"width": 840,
"height": 168,
"caption": "Biocodex"
},
"image": {
"@id": "https://www.biocodex.com/en/#/schema/logo/image/"
},
"sameAs": [
"https://x.com/microbiota_inst",
"https://www.linkedin.com/company/biocodex/"
]
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
✓ Less BS than average
Biocodex has 6.7 points less BS than the average for Medical Devices, Pharma & Biotech.
BS Detector
Medical Devices, Pharma & Biotech BS: Biocodex (biocodex.com)
https://biocodex.com
📍 Industry: Medical Devices, Pharma & Biotech
34
BS / 100
Biocodex is a high-substance pharmaceutical entity that occasionally hides its light under a bushel of standard corporate fluff. The BS score is kept low by the granular financial and clinical details provided in its news and heritage sections, despite the presence of unverified ‘trust theatre’ review counts.
Info Density
Power-words vs. Substance ratio.
8
27% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
10
50% BS
Commodity Fingerprint
Detection of industry clichés/templates.
9
60% BS
Identity & Authority
Expert verifiability & Schema depth.
5
33% BS
Eliminate unverified review counts that lack direct links to third-party platforms to resolve the trust theatre flag. Replace fluff-heavy headings like ‘Empowering everyone to live fully’ with descriptive ones that highlight your actual footprint, such as ’70 Years of Microbiota Innovation.’ Implement Person schema for the CEO and key scientific leads to bridge the authority gap. Add outbound citations or source links for market leadership claims in the Women’s Health section.
The content perfectly aligns with the Medical Devices, Pharma & Biotech category. It explicitly details pharmaceutical manufacturing (Beauvais industrial site), drug licensing agreements (THX Pharma), clinical trial preparations (Phase 3 for Batten-1), and specific therapeutic areas like microbiota care and orphan diseases.
“The score of 34 indicates a low-BS, high-substance site. The primary drivers of the score were Trust and Proof (10/20) due to unverified review counts and Commodity Fingerprint (9/15) due to the use of standard pharma-marketing templates. The site's Information Density and Semantic Coherence are very strong, significantly lowering the overall BS rating.”
Verified Analysis Date: May 29, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Biocodex, captured on May 29, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Biocodex: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://biocodex.com to view the most current version of its content and learn from the source what this company is about and what it offers.